Autogenomics
Prescient Medicine, Erasmus MC Partner to Study Opioid Addiction Risk Test
Prescient offers a test that is designed to determine an individual's risk of opioid addiction by analyzing 16 genes in the brain's reward pathway.
Prescient Medicine Acquires AutoGenomics
Prescient will further the development and commercialization of the Infiniti Neural Response Panel to identify patients who may be at risk for opioid use disorder.
FDA Grants Breakthrough Designation for AutoGenomics' Infiniti Neural Response Panel
The designation will help the company accelerate the process of bringing the opioid addiction risk test through regulatory review and clearance.
The company joins others in a still-controversial setting, hoping to market its test to help guide the prescription of narcotic pain medications.
WuXi to Distribute AutoGenomics' MDx System in China
The companies will also collaborate on new diagnostic technologies and products that are specifically designed for Chinese patients.
Jul 24, 2015
Oct 8, 2014
AutoGenomics Seeks to Raise $60M in IPO
Apr 8, 2014
Nov 4, 2013
MDx Firm AutoGenomics Withdraws IPO
Aug 29, 2013
Feb 25, 2013
Most Viewed Articles on GWDN Last Week: Feb 25, 2013
Feb 18, 2013
AutoGenomics Withdraws IPO for Second Time
Jan 23, 2013
AutoGenomics Lowers Proceeds Expected from IPO
Sep 27, 2012
AutoGenomics Targets $65M IPO
Jun 27, 2012
AutoGenomics Gets Health Canada OK for PGx System
Mar 28, 2012
Feb 15, 2012
May 19, 2011